<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789112</url>
  </required_header>
  <id_info>
    <org_study_id>12-032</org_study_id>
    <nct_id>NCT01789112</nct_id>
  </id_info>
  <brief_title>Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizier III System in Patients With Heart Failure</brief_title>
  <official_title>Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizier III System in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electric stimulation by cardial contractility modulation (CCM)to improve contractility and
      physical capacity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>positive inotropic effects by CCM stimulation</measure>
    <time_frame>15 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>CCM Implantation</condition>
  <arm_group>
    <arm_group_label>CCM aggregate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking of 10 blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Taking of blood sample</description>
    <arm_group_label>CCM aggregate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  planned CCM Implantation

          -  systolic left ventricular dysfunction despite of adequate therapy of heart failure
             (NYHA II, III, IV)

          -  implanted pacemaker, defibrillatoror or pacemaker  during CS intubation

          -  written informed consent

          -  open entryways

        Exclusion Criteria:

          -  anemia HB&lt;8 mg/dl

          -  lying CS tube or CS being not able to intubate

          -  chronic atrial fibrillation or flutter

          -  mechanic tricuspid valve prothesis

          -  no acces via subclavian vein

          -  patients with VVI pacemaker being stimulated 110%

          -  idiopathic hypertrophic cardiomyopathy, restrictiv constrictiv cardiomyopathy or
             heart failure because of known inflammatory or infiltrative illnesses or constrictive
             illness

          -  acute myocardial ischemia presented by angina pectoris or ECG changes under load

          -  patients being hospitalized because of heart failure during the last month and have
             to be treated with intravenous diuretics or inotropic subtances

          -  acute coronary syndrome should not be implanted for at least 3 month

          -  patients with mechanic aortic or tricuspid valve

          -  patients after heart transplantation

          -  patients with clinical significant ectopy, defined by &gt; 8.900 PVCs during 24 hours at
             beginning Holter monitoring

          -  patients after hyperttensive crisis

          -  patients with acute renal failure

          -  EF &gt; 35

          -  patients after left ventricular pacemaker electrode

          -  pregnant or breast feeding women

          -  patients with heart failure after sepsis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Schauerte, Prof. Dr. med., MD</last_name>
    <phone>+49 241 80 89301</phone>
    <email>pschauerte@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>North Rhine Westfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Schauerte, Prof. Dr. med., MD</last_name>
      <phone>+49 241 80 89669</phone>
      <email>pschauerte@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 8, 2013</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
